Frier Levitt partner Edgar Asebey is featured in The Wall Street Journal article, “How the FDA Is Taking Aim at the Surreal World of TV Drug Ads.” The piece explains that the FDA, under directive from President Trump, has launched a major crackdown on misleading pharmaceutical direct-to-consumer (DTC) ads. The agency issued around 100 letters warning drugmakers about ads that overhype drug effectiveness or create unrealistic expectations of cures.
Edgar highlights that the FDA’s message to companies is that it wants consumers to get an accurate depiction of a drug’s risks and benefits. He also notes that drug ads are a priority of the administration, and the FDA is likely to shift resources from other areas to follow through on its commitment.
Read the article on wsj.com.